To see the safety and efficacy of Mulmina D in improving the overall general health, physical, psychological and quality of life, in geriatric volunteers.

A PROSPECTIVE, OPEN LABEL, RANDOMIZED, CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY OF MULMINA-D MANGO (READY TO DRINK) IN IMPROVING THE OVERALL GENERAL WELL-BEING IN GERIATRIC POPULATION.

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/10/037286

Enrollment

100

Registered

2021-10-12

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Mulmina-D Mango ready to drink: Dose: 200ml Dosage form: Oral Drink Frequency : 2 times daily Route of administrate : Orally Total duration: 30 days Control Intervention1: Mild diabetic

Eligibility

Inclusion criteria

Inclusion criteria: i. Individual is at least 55 years old but not older than 85 years ii. Diabetic subjects who are non-insulin dependent (NIDD) iii. Individual is not simultaneously enrolled in another program promoting either well-being or physical activity iv. Individual is with mild to moderate hypertensive, diabetic or other co-morbidities that are of no immediate life threatening to the volunteer v. Subjects willing to refrain from using any external supplements like Vitamins and Minerals during the trial period.

Exclusion criteria

Exclusion criteria: i. Pregnancy or breast feeding. ii. Evidence of significant uncontrolled co-morbid diseases which in the investigators opinion would jeopardize patient participation. iii. History of cancer, including solid tumors, hematologic malignancies and carcinoma in situ. iv. Any neurological congenital or acquired vascular or systemic disorder which could affect any of the efficacy assessments. v. Participation in the current or previous treatment with any approved or investigational health supplements during the past 1 month.

Design outcomes

Primary

Measure	Time frame
Ã¢â?¬Â¢ Change in the hematology, biochemical and vital parameters from Day 0 to Day 30 towards safety assessments Ã¢â?¬Â¢ Change in WBSE scale, General well-being scale on mini nutritional scale, Geriatric depression scale and Barthel index from Day 0 to Day 30. Ã¢â?¬Â¢ Change in Plasma ATP levels, Cortisol, DHEA, SOD, Vitamin E & C, IgG, IgD, IgM, IL-6 and TNF alpha from Day 0 to Day 30. Timepoint: Day 0, 15 and 30	—

Measure

Time frame

Ã¢â?¬Â¢ Change in the hematology, biochemical and vital parameters from Day 0 to Day 30 towards safety assessments Ã¢â?¬Â¢ Change in WBSE scale, General well-being scale on mini nutritional scale, Geriatric depression scale and Barthel index from Day 0 to Day 30. Ã¢â?¬Â¢ Change in Plasma ATP levels, Cortisol, DHEA, SOD, Vitamin E & C, IgG, IgD, IgM, IL-6 and TNF alpha from Day 0 to Day 30. Timepoint: Day 0, 15 and 30

—

Secondary

Measure	Time frame
Assessing the overall health of geriatric populationTimepoint: Day 0 to Day 30	—

Countries

India

Contacts

Public ContactMr Raghavendra K V

Radiant Research Services Pvt. Ltd

ashok@radiantresearch.in9880999297

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026